TEVA

31.89

0.47% 0.15

Dopo l'orario di chiusura: 32.03 0.14 +0.44%

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TEVA Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$31.74

Aprire:

$31.53

Volume 24 ore:

2.62M

Relative Volume:

0.24

Capitalizzazione di mercato:

$36.59B

Reddito:

$16.88B

Utile/perdita netta:

$666.71M

Rapporto P/E:

52.01

EPS:

0.6132

Flusso di cassa netto:

$251.19M

1 W Prestazione:

+5.07%

1M Prestazione:

+21.16%

6M Prestazione:

+92.57%

1 anno Prestazione:

+40.98%

Intervallo 1D:

$31.47

$31.89

Intervallo di 1 settimana:

$30.50

$31.99

Portata 52W:

$12.46

$31.99

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Nome

Teva Pharmaceutical Industries Ltd Adr

Settore

Healthcare (1131)

Industria

Drug Manufacturers - Specialty & Generic (84)

Telefono

972 (3) 914-8213

Indirizzo

TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV

Dipendente

35,686

Cinguettio

@TevaUSA

Prossima data di guadagno

2025-01-29

Ultimi documenti SEC

TEVA's Discussions on Twitter

Confronta TEVA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TEVA Teva Pharmaceutical Industries Ltd Adr	31.89	36.41B	16.88B	666.71M	251.19M	0.6132
ZTS Zoetis Inc	126.23	55.30B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	15.65	49.22B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	10.13	44.97B	14.26B	1.98B	2.47B	0.4327
UTHR United Therapeutics Corp	507.16	22.16B	3.08B	1.24B	1.07B	25.61

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-09	Iniziato	Barclays	Overweight
2025-12-05	Iniziato	Scotiabank	Sector Outperform
2025-06-06	Iniziato	Goldman	Buy
2025-05-28	Iniziato	Truist	Buy
2025-05-12	Aggiornamento	JP Morgan	Neutral → Overweight
2024-07-10	Aggiornamento	Argus	Hold → Buy
2024-03-08	Aggiornamento	JP Morgan	Underweight → Neutral
2024-02-12	Aggiornamento	Piper Sandler	Neutral → Overweight
2024-01-23	Aggiornamento	Jefferies	Hold → Buy
2024-01-03	Aggiornamento	Piper Sandler	Underweight → Neutral
2023-12-18	Iniziato	HSBC Securities	Buy
2023-11-27	Aggiornamento	UBS	Neutral → Buy
2023-07-06	Aggiornamento	UBS	Sell → Neutral
2023-05-25	Iniziato	Morgan Stanley	Equal-Weight
2023-05-18	Aggiornamento	Evercore ISI	In-line → Outperform
2023-01-19	Downgrade	Jefferies	Buy → Hold
2022-11-14	Downgrade	JP Morgan	Neutral → Underweight
2022-11-04	Downgrade	UBS	Neutral → Sell
2022-10-21	Ripresa	Jefferies	Buy
2022-08-05	Aggiornamento	BofA Securities	Neutral → Buy
2022-06-14	Ripresa	UBS	Neutral
2022-05-17	Aggiornamento	BofA Securities	Underperform → Neutral
2022-05-04	Downgrade	Piper Sandler	Neutral → Underweight
2022-04-05	Aggiornamento	Barclays	Equal Weight → Overweight
2022-03-25	Aggiornamento	Bernstein	Mkt Perform → Outperform
2022-01-27	Downgrade	Argus	Buy → Hold
2021-10-28	Downgrade	Raymond James	Outperform → Mkt Perform
2021-05-04	Downgrade	UBS	Buy → Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Sector Perform
2020-11-25	Iniziato	Oppenheimer	Perform
2020-08-06	Aggiornamento	Barclays	Underweight → Equal Weight
2020-07-27	Ripresa	Goldman	Neutral
2020-06-01	Aggiornamento	SunTrust	Hold → Buy
2020-04-24	Ripresa	Citigroup	Neutral
2020-04-06	Aggiornamento	UBS	Neutral → Buy
2020-02-24	Downgrade	Edward Jones	Hold → Sell
2019-11-12	Aggiornamento	JP Morgan	Underweight → Neutral
2019-10-17	Aggiornamento	Gabelli & Co	Hold → Buy
2019-08-07	Downgrade	Evercore ISI	Outperform → In-line
2019-07-19	Iniziato	Wolfe Research	Peer Perform
2019-07-15	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2019-07-10	Ripresa	Credit Suisse	Neutral
2019-07-05	Aggiornamento	Argus	Hold → Buy
2019-06-11	Iniziato	Barclays	Underweight
2019-06-03	Aggiornamento	Oppenheimer	Perform → Outperform
2019-05-30	Downgrade	BofA/Merrill	Buy → Underperform
2019-05-28	Downgrade	UBS	Buy → Neutral
2019-03-20	Iniziato	SunTrust	Hold
2019-03-07	Ripresa	UBS	Buy

Mostra tutto

Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie

Dec 22, 2025

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play - Finviz

Dec 22, 2025

Dec 19, 2025

Teva Pharma stock hits 52-week high at 30.45 USD - Investing.com India

Dec 19, 2025

Dec 18, 2025

Teva (TEVA): Assessing Valuation After a 65% Three‑Month Share Price Surge - Sahm

Dec 18, 2025

Dec 17, 2025

BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz

Dec 17, 2025

3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today - The Motley Fool

Dec 17, 2025

Dec 16, 2025

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 16, 2025

Dec 14, 2025

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - Finviz

Dec 14, 2025

Has Teva’s 80% One Year Surge Run Ahead of Its Fundamental Valuation in 2025? - Sahm

Dec 14, 2025

Dec 13, 2025

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 - Sahm

Dec 13, 2025

Dec 12, 2025

Teva Releases Q4 2025 Aide Memoire - Sahm

Dec 12, 2025

Dec 11, 2025

Teva (NYSE:TEVA) Valuation Check After New Schizophrenia Drug Filing and Growing Growth Optimism - Sahm

Dec 11, 2025

Teva’s FDA Filing For Once-Monthly Schizophrenia Drug Might Change The Case For Investing In TEVA - Sahm

Dec 11, 2025

Teva Pharma stock hits 52-week high at 29.81 USD By Investing.com - Investing.com Nigeria

Dec 11, 2025

Teva (NYSE:TEVA) Valuation Check After Strong Q3, Margin Targets and Deleveraging Drive a Sharp Share Price Rebound - Sahm

Dec 04, 2025

Dec 01, 2025

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

Dec 01, 2025

Nov 30, 2025

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz

Nov 30, 2025

Nov 28, 2025

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm

Nov 28, 2025

Nov 27, 2025

Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm

Nov 27, 2025

Nov 26, 2025

Teva stock hits 52-week high at 26.38 USD - Investing.com

Nov 26, 2025

Nov 25, 2025

Teva Rise Innovation Platform Might Change The Case For Investing In Teva Pharmaceutical Industries (TEVA) - Sahm

Nov 25, 2025

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm

Nov 25, 2025

Nov 19, 2025

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges - Finviz

Nov 19, 2025

Nov 17, 2025